Zusammenfassung
Die Prognose für Patienten mit Hodgkin-Lymphom hat sich in den letzten 30 Jahren erheblich verbessert. In Abhängigkeit von dem Stadium bei Erstdiagnose können mittlerweile Heilungsraten von über 80% erzielt werden. Moderne Therapiestrategien sollen insbesondere das Auftreten von therapiebedingten Spätfolgen bei gleichzeitiger Beibehaltung der guten Tumorkontrolle verringern. Offene Fragen in den fortgeschrittenen Stadien betreffen die optimale Zyklusanzahl bei einer effektiven Chemotherapie und die Notwendigkeit einer zusätzlichen Bestrahlung. Der Stellenwert der PET bezüglich der Unterscheidung zwischen residualen narbigen Veränderungen und aktivem Lymphomgewebe nach intensiver Chemotherapie wird in der aktuellen Studie (HD15) untersucht.
Abstract
High cure rates have been achieved in the treatment for patients with Hodgkin’s lymphoma (HL) in the past 30 years. Depending on stage at diagnosis, more than 80% of patients can be cured with first-line treatment. Modern therapeutic strategies aim at both reducing therapy-induced late toxicities while maintaining effective tumor control. Questions to be answered in the treatment of advanced stages concern the optimal number of cycles for an effective chemotherapy regimen and the necessity for additional radiation therapy. The role of PET in differentiating between residual scar tissue and active lymphoma is being evaluated in the ongoing trial (HD15).
This is a preview of subscription content, log in via an institution to check access.
Literatur
Aleman BM, Raemaekers JM, Tirelli U et al. (2003) Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med 348:2396–406
Bonadonna G, Zucali R, Monfardini S et al. (1975) Combination chemotherapy of Hodgkin‘s disease with adriamycin, bleomycin, vinblastine, and imidazole carboximide versus MOPP. Cancer 36:252–259
Canellos GP, Anderson JR, Propert KJ et al. (1992) Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478
Connors JM, Klimo P, Adams G et al. (1997) Treatment of advanced Hodgkin‘s disease with chemotherapy — comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15:1638–1645
de Wit M, Bohuslavizki KH, Buchert R et al. (2001) 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin’s lymphoma. Ann Oncol 12:29–37
Diehl V, Franklin J, Pfreundschuh M et al. (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 348:2386–2395
Diehl V, Brillant C, Franklin J et al. (2004) BEACOPP chemotherapy for Advanced Hodgkin’s Disease: Results of Further Analyses of the HD9- and HD12- Trials of the German Hodgkin Study Group (GHSG). Blood 104 A: 307
Duggan DB, Petroni GR, Johnson JL et al. (2003) Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol 21:607–614
Goldie JH, Coldman AJ (1979) A mathematical model for relating the drug sensitivity of tumors to the spontaneous mutation rate. Cancer Treat Rep 63:1727–1733
Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 339:1506–1514
Loeffler M, Brosteanu O, Hasenclever D et al. (1998) Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin’s disease. International Database on Hodgkin’s Disease Overview Study Group. J Clin Oncol 16:818–829
Longo DL, Young RC, Wesley M et al. (1986) Twenty years of MOPP chemotherapy for Hodgkin‘s disease. J Clin Oncol 4:1295–1306
Santoro J, Bonadonna G, Valagussa P et al. (1987) Long-term results of combined chemotherapy–radiotherapy approach in Hodgkin’s disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5:27
Sieber M, Bredenfeld H, Josting A et al. (2003) 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin’s lymphoma: results of a pilot study of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21:1734–1739
Sieber M, Tesch H, Pfistner B et al. (2004) Treatment of advanced Hodgkin’s disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin’s Lymphoma Study Group HD6 trial. Ann Oncol 15:276–282
Viviani S, Bonadonna G, Santoro A et al. (1996) Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin‘s Disease: Ten-year results. J Clin Oncol 14:1421–1430
Weihrauch MR, Re D, Scheidhauer K et al. (2001) Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 98:2930–2934
Interessenkonflikt:
Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Behringer, K., Diehl, V. Behandlung fortgeschrittener Stadien des Hodgkin-Lymphoms. Onkologe 11, 942–947 (2005). https://doi.org/10.1007/s00761-005-0922-5
Issue Date:
DOI: https://doi.org/10.1007/s00761-005-0922-5